Wang, F., Li, Z., Long, X., Wu, D., Cai, X., He, Q., Huang, W., Zhou, L., Zhang, Y., Wang, S. (2026). Real-world efficacy and safety of iruplinalkib in ALK -positive advanced lung adenocarcinoma patients previously treated with lorlatinib.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e20730